If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Taltz ® (ixekizumab) injection
80 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
TALTZ® (ixekizumab): Doses Greater than 80 mg
Neither efficacy nor safety has been adequately studied for dosage greater than that described in the prescribing information.
Psoriasis
Ixekizumab is administered by SC injection. The recommended dose is
-
160 mg (two 80-mg injections) at week 0
-
80 mg at weeks 2, 4, 6, 8, 10, and 12, then
-
80 mg Q4W.1
Psoriatic Arthritis
Ixekizumab is administered by SC injection. The recommended dose is
-
160 mg (two 80-mg injections) at week 0, then
-
80 mg Q4W.1
For patients with PsA and coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for plaque psoriasis.1
Axial Spondyloarthritis
Ixekizumab may be administered alone or in combination with a cDMARD (eg, MTX).1
Radiographic Axial Spondyloarthritis/Ankylosing Spondylitis
Ixekizumab is administered by SC injection. The recommended dose is
-
160 mg (two 80-mg injections) at week 0, then
-
80 mg Q4W.1
Nonradiographic Axial Spondyloarthritis
Ixekizumab is administered by SC injection. The recommended dose is 80 mg Q4W.1
Enclosed Prescribing Information
TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly
1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
cDMARD = conventional disease-modifying antirheumatic drug
MTX = methotrexate
PsA = psoriatic arthritis
Q4W = every 4 weeks
SC = subcutaneous
Date of Last Review: October 22, 2020